Member Info for Titania

https://cantreatcovid.org/about/

But what is being trialled? Not announced as yet as far as I can see.

Also video:-

https://youtu.be/kOElXhP74Ug

Apologies if already posted.

Synairgen podcast

https://youtu.be/YP5AzQnETm0

Sorry if already posted.

Is it because Shionogi signed this:-

https://www.pmlive.com/pharma_news/shionogi_signs_licence_agreement_with_mpp_for_covid-19_oral_antiviral_treatment_1456349

Why advance Scorpio-HR and not advance SNG001. Is that the real question we are asking?

Sabizabulin video discussion following IDweek in October. Also a late breaking Covid presentation. Sounds no better than SNG001 and is being presented to the FDA in November!
No reported dialogue with the FDA for SNG001 by Synairgen though!
Video report in first five minutes.

https://www.medscape.com/viewarticle/983360

"Research projects will be coming soon."

https://www.southampton.ac.uk/people/5wzg2s/professor-paul-little

Professor Paul Little was involved in the Panoramic Adaptive Platform Trial

https://www.southampton.ac.uk/medicine/academic_units/projects/panoramic.page?

https://upstreamlab.org/project/can-treat-covid/

Contact in Southampton is Professor Paul Little.

https://www.southampton.ac.uk/people/5wzg2s/professor-paul-little

"To ensure the findings are shared widely and effectively, the CanTreatCOVID team will also work closely with APTs in the United Kingdom and European Union."

https://cantreatcovid.org/about/

"Nope, other than that Faron are supposed to be having FDA meetings this quarter, also in discussion with DofD regarding Traumakine , and also at Jefferies Conference in London .
They are hoping to get a Bexmab poster out too in November .
Could just be rumblings of some good news from any of those areas .
I've been checking what I can , but apart from a new patent , nothing much else to go on this week ."

From the Faron board. Not a cross ramp but an example of how other companies are kept informed of what is happening in a way that we do not seem to be!

CBD S&T conference 6-9 Dec 2022
"Novel broad-spectrum therapeutic candidates that are efficacious against bioweapon (BW) threats are needed for evaluation, as are broad spectrum discovery and evaluation platforms. Such candidates and platforms will help to build a therapeutic armamentarium, with associated safety and efficacy data that can be used to advance therapeutic candidates against BW threats for FDA approval, as well as serve as a platform for countering emerging threats of the future. Approaches being considered (but NOT limited to) are:

Identification of pathogen and/or host based targets common to virus families
Platforms for discovery and evaluation of broad-spectrum therapeutics
Therapeutics targeting viral disease pathways that cause acute morbidity/mortality (e.g. encephalitic inflammation)"

https://cbdstconference.com/review-sessions/

Apologies if already posted.

University of Southampton listed as a partner and jobs might give an idea of timing and length of trial.

https://cantreatcovid.org/partners/

https://www.recruitingsite.com/csbsites/unityhealth/JobDescription.asp?lang=en&JobNumber=906910

https://cantreatcovid.org

I'd go back in time and sell when Leonard Licht did!

Funding opened 10/18/22!

Could we qualify for Drive funding?

https://drive.hhs.gov/host_tx.html

Don't think this is of much consequence but posting as connected to Activ2 and Pandemic Preparedness:-

https://www.unc.edu/posts/2022/10/28/unc-school-of-medicine-awarded-3-million-for-emerging-pathogen-preparedness-and-training/

Here's the link for the jobs advertised

https://www.google.com/search?client=safari&rls=en&q=hobson+prior+job+southampton&ie=UTF-8&oe=UTF-8&ibp=htl;jobs&sa=X&ved=2ahUKEwjh9cuTr6b7AhVOXMAKHSjbBrsQkd0GegQICxAB#fpstate=tldetail&htivrt=jobs&htiq=hobson+prior+job+southampton&htidocid=nzUaRJhxr74AAAAAAAAAAA%3D%3D